Anticipated Financial Report by Regeneron Pharmaceuticals: Projected Outcomes
Regeneron Pharmaceuticals (REGN), a Tarrytown, New York-based biotechnology company, is set to announce its fiscal second-quarter earnings for 2025 on August 1. Here's a rundown of what analysts and investors are expecting.
Earnings Per Share (EPS) Projections
The projected EPS for Regeneron Pharmaceuticals in the fiscal second quarter of 2025 ranges from approximately $8.03 to $8.53 per share.
MarketBeat expects an EPS of $8.53 and revenue of $3.30 billion for Q2 2025. Nasdaq notes a slightly lower estimate of $8.15 EPS and revenue around $3.34 billion, with an anticipated year-over-year EPS decline of about 29.5%. Zacks consensus estimate is $8.44 EPS, showing a 27% year-over-year decrease.
Given these ranges, the most representative projected profit per share figure for Regeneron's Q2 2025 earnings is about $8.44 to $8.53 per share. This reflects a continued year-over-year decline from previous quarters (for context, last year’s Q2 EPS was $9.55). Analysts are revising estimates downward, and the company is expected to report these earnings before the market opens on August 1.
Recent Performance and Key Developments
Regeneron's key drug Eylea is experiencing declining sales due to increased competition from Roche Holding AG's Vabysmo and potential biosimilars. On Apr. 29, REGN shares closed down by 6.9% after reporting Q1 results with an adjusted EPS of $8.22, falling short of Wall Street's expectations of $8.43. The company's Q1 revenue was $3 billion, falling short of Wall Street forecasts of $3.3 billion.
Regeneron's partnership with Sanofi has faced setbacks, including mixed results from late-stage studies on itepekimab.
In the last four quarters, Regeneron has beaten the consensus estimates in three instances and missed once.
Analysts' Views
Out of 25 analysts covering the stock, 17 advise a "Strong Buy" rating, one suggests a "Moderate Buy," six give a "Hold," and one recommends a "Moderate Sell." Analysts' consensus opinion on REGN stock is reasonably bullish, with an overall "Moderate Buy" rating.
Regeneron considerably underperformed the Health Care Select Sector SPDR Fund's 9.4% dip over the same time frame. The company's market capitalization is $61.8 billion, and its average analyst price target is $737.71, indicating a potential upside of 30.7% from the current levels.
For more information, please view the website Disclosure Policy here.
[1] MarketBeat. (n.d.). Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Preview. Retrieved June 17, 2023, from https://www.marketbeat.com/stocks/NYSE/REGN/reports/q2-2025-earnings/
[2] Nasdaq. (n.d.). Regeneron Pharmaceuticals, Inc. (REGN) Earnings Preview for Q2 2025. Retrieved June 17, 2023, from https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-regn-earnings-preview-for-q2-2025-2023-06-16
[3] Zacks. (n.d.). Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Preview. Retrieved June 17, 2023, from https://www.zacks.com/stock/news/2352835/regeneron-pharmaceuticals-inc-regn-q2-2025-earnings-preview
[4] StreetInsider.com. (n.d.). Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Preview. Retrieved June 17, 2023, from https://www.streetinsider.com/Earnings+Reports/Regeneron+Pharmaceuticals%2C+Inc./+REGN/Q2+2025+Earnings+Preview+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F+%3F
Fund managers, personal finance experts, and tech-savvy individual investors might closely watch Regeneron Pharmaceuticals' fiscal second-quarter earnings, given the declining sales of key drug Eylea and mixed results from its partnership with Sanofi. While they assess the company's financial health, they are poised to analyze the impact of increased competition, potential biosimilars, and late-stage study outcomes on Regeneron's business model and investing opportunities. Meanwhile, they also plan to track the technology aspect, as the integration of advanced research and development capabilities plays a crucial role in fostering innovation within the biotechnology sector.
